![Trials will evaluate vaccine's ability to elicit immune responses against a spectrum of HIV-1 strains.[4designersart-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/May6_2011_22401855_GreenOrangeRedHIV_VirologyInstituteGetsHIVVaccineFunding3978120126-218x150.jpg "Multiple Sclerosis Drug Inhibits HIV Infection and Transmission in Human Immune Cells")
Cytiva will also look to grow through expanded activity in cell and gene therapies—and additional work with customers working toward COVID-19 drugs, vaccines, and tests . . .
- Bioprocessing
- Genome Editing
- Gene Therapy
- Virology
- Coronavirus
- Drug Discovery
- Chromatography
- Tangential Flow
- Therapeutics
- Biologics
- GEN Edge
- Cell Therapy
- Danaher
- GE Healthcare
- Cell Culture
- Single-Use Systems
Cytiva Picks Up Where GE Leaves Off after $21B Deal
Danaher Pursues Expanded Activity in Cell and Gene Therapies, Additional Work with Customers Developing COVID-19 Drugs, Vaccines, and Tests.
Danaher has re-branded and re-launched the BioPharma business of GE Healthcare Life Sciences under the name Cytiva, after completing its $21.4 billion acquisition of the former GE Healthcare Life Sciences. Cytiva aims to grow its tools, tech, and services businesses, with a focus on cell and gene therapy, and a presence in the development of COVID-19 drugs, vaccines, and tests. [Cytiva]
